P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.
暂无分享,去创建一个
Yukio Kato | Akira Tsuji | Yoshiyuki Kubo | Katsuaki Ito | Y. Kato | A. Tsuji | Y. Kubo | T. Wakayama | S. Iseki | Tomohiko Wakayama | Shoichi Iseki | Hai Thien Nguyen | Katsuaki Ito | H. T. Nguyen
[1] L. Bolund,et al. Side population cells in human and mouse epidermis lack stem cell characteristics. , 2004, Experimental cell research.
[2] T. Tsuruo,et al. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. , 1992, Life sciences.
[3] Y. Kato,et al. Organic Cation/Carnitine Transporter OCTN2 (Slc22a5) Is Responsible for Carnitine Transport across Apical Membranes of Small Intestinal Epithelial Cells in Mouse , 2006, Molecular Pharmacology.
[4] Y. Kato,et al. Involvement of organic anion transport system in transdermal absorption of flurbiprofen. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[5] Thierry Buclin,et al. Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.
[6] C. Harding. The stratum corneum: structure and function in health and disease , 2004, Dermatologic therapy.
[7] J. Heykants,et al. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. , 1987, Journal of chromatography.
[8] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[9] M. Fromm,et al. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. , 2006, Fundamental & clinical pharmacology.
[10] J. Watson,et al. Neonatal murine epidermal cells express a functional multidrug-resistant pump. , 2000, The Journal of investigative dermatology.
[11] T. Tsuruo,et al. P-Glycoprotein-Mediated Transport of Itraconazole across the Blood-Brain Barrier , 1998, Antimicrobial Agents and Chemotherapy.
[12] N. Jain,et al. Liquid crystalline pharmacogel based enhanced transdermal delivery of propranolol hydrochloride. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[13] B. W. Barry,et al. Novel mechanisms and devices to enable successful transdermal drug delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] R. Shanks,et al. Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update. , 1987, Clinical pharmacokinetics.
[15] E. Schuetz,et al. Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein , 2002, Journal of Pharmacology and Experimental Therapeutics.
[16] T. Hasegawa,et al. Effect of Endotoxin on P-Glycoprotein-Mediated Biliary and Renal Excretion of Rhodamine-123 in Rats , 2001, Antimicrobial Agents and Chemotherapy.
[17] Y. Chardonnet,et al. Active cell membrane mechanisms involved in the exclusion of RH 123 allow distinction between normal and tumoral cells , 1994, Cell Biology and Toxicology.
[18] T. Terasaki,et al. Physiologically Based Pharmacokinetic Model for β-Lactam Antibiotics I: Tissue Distribution and Elimanation Rates , 1983 .
[19] Y. Tokura,et al. Quinolone photoallergy: photosensitivity dermatitis induced by systemic administration of photohaptenic drugs. , 1998, Journal of dermatological science.
[20] Y. Kato,et al. Characterization of the transdermal transport of flurbiprofen and indomethacin. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[21] Y. Sai,et al. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P‐glycoprotein , 2001, The Journal of pharmacy and pharmacology.
[22] R. Shanks,et al. Clinical Pharmacokinetics of β-Adrenoceptor Antagonists , 1987 .
[23] R. Agarwal,et al. Multiple cytochrome P450 isozymes in murine skin: induction of P450 1A, 2B, 2E, and 3A by dexamethasone. , 1994, The Journal of investigative dermatology.
[24] F. Lammert,et al. Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. , 2003, The Journal of investigative dermatology.
[25] T. Nabeshima,et al. Intracutaneous Distributions of Fluconazole, Itraconazole, and Griseofulvin in Guinea Pigs and Binding to Human Stratum Corneum , 2004, Antimicrobial Agents and Chemotherapy.
[26] S. Frankenberg,et al. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. , 2001, The Journal of investigative dermatology.
[27] G. Mundy,et al. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations , 2006, Osteoporosis International.
[28] Jörg Huwyler,et al. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. , 2003, Journal of medicinal chemistry.
[29] M. Nap,et al. Immunohistochemical detection of P-glycoprotein on frozen and paraffin-embedded tissue sections of normal and malignant tissues. , 1995, Anticancer research.
[30] D. Stevens,et al. Effect of cyclodextrin on the pharmacology of antifungal oral azoles , 1992, Antimicrobial Agents and Chemotherapy.
[31] J. Heykants,et al. Determination of cisapride in plasma and animal tissues by high-performance liquid chromatography. , 1988, Journal of chromatography.
[32] Y. Sai,et al. Active Secretion of Drugs from the Small Intestinal Epithelium in Rats by P‐Glycoprotein Functioning as an Absorption Barrier , 1996, The Journal of pharmacy and pharmacology.
[33] Groen,et al. Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis , 1998, Clinical and experimental dermatology.
[34] A. Tsuji. Transporter-mediated Drug Interactions. , 2002, Drug metabolism and pharmacokinetics.
[35] D. Balayssac,et al. Does inhibition of P-glycoprotein lead to drug-drug interactions? , 2005, Toxicology letters.
[36] M. Waterman,et al. A Keratinocyte-specific Epoxygenase, CYP2B12, Metabolizes Arachidonic Acid with Unusual Selectivity, Producing a Single Major Epoxyeicosatrienoic Acid* , 1998, The Journal of Biological Chemistry.
[37] T. Terasaki,et al. Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.
[38] P. Borst,et al. Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.
[39] M. Waterman,et al. Differentiating Keratinocytes Express a Novel Cytochrome P450 Enzyme, CYP2B19, Having Arachidonate Monooxygenase Activity* , 1998, The Journal of Biological Chemistry.
[40] T. Imai,et al. Multidrug Resistance—Associated Protein 1 Functions as an Efflux Pump of Xenobiotics in the Skin , 2005, Pharmaceutical Research.
[41] T. Terasaki,et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. , 1983, Journal of pharmaceutical sciences.
[42] L. Benet,et al. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.